AGP Picks
View all

CYDUCT's HALO breast fluid system cited in Clinical Proteomics review

Oct. 29, 2026
By AI, Created 13:00 UTC, Oct 29, 2026, AGP -

CYDUCT Diagnostics said its HALO Automated Breast Fluid Collection System was cited in a peer-reviewed review in Clinical Proteomics on breast fluid as a liquid biopsy platform. The citation gives the company independent scientific validation as interest grows in standardized breast ductal sampling for earlier risk assessment and precision breast care.

Why it matters: - The Clinical Proteomics citation gives HALO independent scientific recognition in a peer-reviewed journal. - The review adds momentum to breast ductal fluid research as scientists look for better ways to study the biology where most breast cancers begin. - Standardized breast fluid collection could support earlier detection, risk stratification and more personalized breast healthcare.

What happened: - CYDUCT Diagnostics announced that its HALO Automated Breast Fluid Collection System was cited in a peer-reviewed article in Clinical Proteomics, a Springer Nature journal. - The review is titled "Nipple aspirate fluid as a proximal breast liquid biopsy platform: advancing precision risk management in breast cancer." - The authors wrote: "Further standardization has been achieved with automated devices (e.g., the HALO system)" - Dominick Gatto, CYDUCT Diagnostics CEO, called the citation "an important milestone" and said it underscores the scientific relevance of breast ductal fluid collection.

The details: - The review describes nipple aspirate fluid, or NAF, as a proximal liquid biopsy platform that may provide molecular insight into the local ductal microenvironment. - The article says NAF analysis can examine proteins, metabolites, genetic and epigenetic alterations, extracellular vesicles and other molecular signals. - CYDUCT said HALO’s automated, programmed aspiration cycles are designed to reduce operator dependence and support consistent breast-fluid collection across clinical settings. - The review highlights HALO’s feasibility, safety and high patient acceptance in large-scale screening studies involving asymptomatic women. - The article points to three areas of interest: molecular risk stratification for women with pathologic nipple discharge, individualized biological risk profiling for women at elevated risk or with dense breasts, and monitoring molecular changes tied to treatment response and disease progression. - CYDUCT said more information will be available on the company’s website at CYDUCTDX.com.

Between the lines: - The citation does not prove a clinical breakthrough, but it does signal that HALO has moved into the scientific conversation around standardized breast duct sampling. - The review also shows where the field is headed: toward methods that can complement imaging and other diagnostic tools with molecular data from breast ducts. - The authors also note the need for greater standardization and prospective clinical validation, which suggests broader adoption will depend on more evidence.

What's next: - CYDUCT said it will continue research, clinical innovation and technology development aimed at moving breast fluid collection tools from research into routine clinical practice. - The company said its longer-term goal is to expand access to precision risk assessment, earlier detection and personalized breast healthcare. - CYDUCT also directed readers to OTC Markets filings at OTC Markets for additional risk information tied to forward-looking statements.

The bottom line: - HALO’s citation in a peer-reviewed review gives CYDUCT a notable credibility boost as breast ductal fluid sampling draws more attention in precision breast cancer research.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Health Professional Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Health Professional Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.